Skip to main content
x

ProfileSearch

Provider

Ali Jahanian-Najafabadi

Ali Jahanian-Najafabadi , PhD

Associate Professor



School :

School of Pharmacy and Pharmaceutical Sciences

Department :

Department of Pharmaceutical Biotechnology

Research Center :

Isfahan Pharmaceutical Research Center

work address :

MUI

Education :

2018-2019: Sabbatical leave at University of Waterloo, Waterloo, ON. Canada 2006- 2012: Ph.D. of Pharmaceutical Biotechnology, Pasteur Institute of Iran, Tehran, Iran. 2000-2006: Doctor of Pharmacy (Pharm. D.), School of Pharmacy, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran

Relevant Work Experience :

I hold a Pharm.D. degree from Isfahan University of Medical Sceinces and a Ph.D. degree from Pasteur Institute of Iran. In addition to courses and educational tasks which I handle in Isfahan faculty of pharmacy, I also supervise and manage my research team which is specially focused on production and evaluation of cancer cell targeted recombiant proteins, vaccines and aslo biosimilars.

Professional Memberships & Qualification :

Extra Curricular Activities/ Interest(personal url) :



Grants & Awards :

Patents :

Presentations & Poster Sessions :

Research Experience :

1.    Mitochondrial transplantation ameliorates ischemia/reperfusion-induced kidney injury in rat. Hanieh Jabbari, Amaneh Mohammadi Roushandeh, Mojdeh Kheirandish Rostami, Mohammad Taghi Razavi-Toosi, Mohammad Ali Shokrgozar, Ali Jahanian-Najafabadi, Yoshikazu Kuwahara, Mehryar Habibi Roudkenar. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. Volume 1866, Issue 8, 1 August 2020, 165809 2.    RGD peptide grafted polybutylene adipate-co-terephthalate/gelatin electrospun nanofibers loaded with a matrix metalloproteinase inhibitor drug for alleviating of wounds: an in vitro/in vivo study. Jaleh Varshosaz, Khatereh Arabloo, Nasim Sarrami, Erfaneh Ghassami, Emadeddin Yazdani Kachouei, Monireh Kouhi & Ali Jahanian-Najafabadi. Drug Development and Industrial Pharmacy.46 (3), 3 March 2020, Pages 484-497 3.    Mitochondrial characteristics contribute to proliferation and migration potency of MDA-MB-231 cancer cells and their response to cisplatin treatment. Mojdeh Kheirandish-Rostami, Mehryar Habibi Roudkenar, Ali Jahanian-Najafabadi, Kazuo Tomita, Yoshikazu Kuwahara, Tomoaki Sato, Amaneh Mohammadi Roushandeh. Life Sciences, 244, 1 March 2020, 117339 4.    Expression and one step intein-mediated purification of biologically active human G-CSF in Escherichia coli. Sima, S., Shafiee, F., Jahanian-Najafabadi, A. Mol Biol Rep 47, 2861–2869 (2020) 5.    Design and production of new chimeric reteplase with enhanced fibrin affinity: a theoretical and experimental study. Mohammadi, E., Mahnam, K., Jahanian-Najafabadi, A., Sadeghi, H.M.M. Journal of Biomolecular Structure and Dynamics, 2020. 6.    Targeted Diphtheria Toxin-Based Therapy: A Review Article. Shafiee, F., Aucoin, M.G., Jahanian-Najafabadi, A. Frontiers in Microbiology. 10: 18 October 2019, Article number 2340 7.    Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity. Sadeghian-Rizi, T, Behdani, M, Khanahmad, H, Ghasemi-Dehkordi, P, Mirmohammad Sadeghi, H, Jahanian-Najafabadi, A. International Journal of Peptide Research and Therapeutics. Volume 25, Issue 2, 1 June 2019, Pages 535-540. 8.    HER-2 aptamer-targeted Ecoflex® nanoparticles loaded with docetaxel promote breast cancer cells apoptosis and anti-metastatic effect. Ghassami E, Varshosaz J, Mirian M, Jahanian-Najafabadi A. IET Nanobiotechnol. 2019; 13(4):428-434. 9.    A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines. Soleimani, M  Sadeghi, HM; Jahanian-Najafabadi, A. Iran J Pharm Res. 2019 Spring: 18(2): 735-744 10.    Generation and Characterization of a Functional Nanobody against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis. Sadeghian-Rizi T, Behdani M, Khanahmad H, Sadeghi HM, Jahanian-Najafabadi A. CNS Neurol Disord Drug Targets. 2019;18(2):141-148. 11.    Preparation and Characterization of Spray-Dried Inhalable Powders Containing Polymeric Micelles for Pulmonary Delivery of Paclitaxel in Lung Cancer. Rezazadeh M, Davatsaz Z, Emami J, Hasanzadeh F, Jahanian-Najafabadi A. J Pharm Pharm Sci. 2018;21(1s):200s-214s. 12.    Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges. Sadeghian-Rizi T, Khanahmad H, Jahanian-Najafabadi A. CNS Neurol Disord Drug Targets. 2018;17(7):496-508. 13.    Lipocalin2 Protects Human Embryonic Kidney Cells against Cisplatin-Induced Genotoxicity. Sadeghi F, Etebari M, Habibi Roudkenar M, Jahanian-Najafabadi A. Iran J Pharm Res. 2018 Winter;17(1):147-154. 14.    A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. Emami J, Rezazadeh M, Mashayekhi M, Rostami M, Jahanian-Najafabadi A. Drug Dev Ind Pharm. 2018 May;44(5):729-740. 15.    Recombinant Production and Intein-Mediated Purification of an Antimicrobial Peptide, BR2. Shafiee, F., Minaiyan, G., Moazen, F., Jahanian-Najafabadi, A. International Journal of Peptide Research and Therapeutics. Volume 23, Issue 4, 1 December 2017, Pages 501-507 16.    Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. Shafiee F, Rabbani M, Jahanian-Najafabadi A. J Microbiol Methods. 2016 Nov;130:100-105 17.    Targeted Delivery of Docetaxel by Use of Transferrin/Poly(allylamine hydrochloride)-functionalized Graphene Oxide Nanocarrier. Nasrollahi, F., Varshosaz, J., Khodadadi, A.A., Lim, S., Jahanian-Najafabadi, A. ACS Applied Materials and Interfaces, Volume 8, Issue 21, Pages 13282-13293 18.    Theoretical design of a new chimeric protein for the treatment of breast cancer. Soleimani, M., Mahnam, K., Mirmohammad-Sadeghi, H., Sadeghi-Aliabadi, H., Jahanian-Najafabadi, A. Research in Pharmaceutical Sciences, Volume 11, Issue 3, 2016, Pages 187-199 19.    Adenovirus-mediated over-expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury. Mohammadzadeh-Vardin, M.a, Roudkenar, M.H.b , Jahanian-Najafabadi, A. Advanced Pharmaceutical Bulletin, Volume 5, Issue 2, 2015, Pages 201-20 20.    In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments: In vitro augmentation of mesenchymal stem cells viability. Amiri F, Jahanian-Najafabadi A, Roudkenar MH. Cell Stress Chaperones. 2015 Mar;20(2):237-51. 21.    Antigenicity and immunogenicity of fused B-subunit of heat labile toxin of Escherichia coli and colonization factor antigen I polyepitopes. Savar NS, Dashti A, Darzi Eslam E, Jahanian-Najafabadi A, Jafari A. J Microbiol Methods. 2014 Nov;106:40-6.

Research Interests :



Teaching Experience :

Teaching Interests :